Dallah’s profit rises 31% to SAR 471.2M in 2024; Q4 at SAR 113.9M

Dallah’s profit rises 31% to SAR 471.2M in 2024; Q4 at SAR 113.9M

05/03/2025 Argaam Exclusive

View other reports

Dallah Healthcare Co. reported a net profit of SAR 471.2 million for 2024, an increase of 31% from SAR 360.1 million a year earlier.



Financials (M)

Item 2023 2024 Change‬
Revenues 2,942.90 3,205.73 8.9 %
Gross Income 1,078.67 1,206.84 11.9 %
Operating Income 506.31 567.12 12.0 %
Net Income 360.12 471.20 30.8 %
Average Shares 97.68 97.68 -
Earnings Per Share before unusual items 3.69 4.82 30.8 %
EPS (Riyals) 3.69 4.82 30.8 %

The annual net profit was propelled by an 8.9% year-on-year (YoY) rise in revenue to SAR 3.20 billion, thanks to increased operating capacity, performance efficiency and the continued growth in the number of patients.

 

The company also cited an 11.9% YoY increase in gross profit to SAR 1.20 billion. The performance of associates improved, as they recorded profits of SAR 43 million in 2024, against a loss of SAR 2 million last year. Gross profit margins expanded to 37.6% in 2024, from SAR 36.7% a year earlier.

 

The full-year earnings before interest, taxes, depreciation and amortization (EBITDA) increased by 19.1% YoY to SAR 751 million.



Current Quarter Comparison (M)

Compared With The
Item Q4 2023 Q4 2024 Change‬
Revenues 806.01 808.76 0.3 %
Gross Income 295.94 292.76 (1.1 %)
Operating Income 134.34 115.40 (14.1 %)
Net Income 113.65 113.90 0.2 %
Average Shares 97.68 97.68 -
Earnings Per Share before unusual items 1.16 1.17 0.2 %
EPS (Riyals) 1.16 1.17 0.2 %

The fourth-quarter net earnings were almost flat at SAR 113.9 million, compared to SAR 113.6 million in Q4 2023.
 

However, net earnings decreased by 9.7% quarter-on-quarter (QoQ) from 126.1 million in Q3 2024.

 

Total shareholders’ equity, after minority interest, increased to SAR 3.46 billion as of Dec. 31, 2024, from SAR 3.20 billion a year earlier.

 

Attached Documents ​

 

View More Financial Results

 


Profit Performance (Million)

Period Net Income Change EPS(Riyal) Extraordinary Income/Expense Net Profit Before Unusual Items Earnings Per Share before unusual items
Q1 2015 47.82 18.1 % 0.53 13.75 34.07 0.38
Q2 2015 35.86 4.4 % 0.40 - 35.86 0.40
Q3 2015 26.78 22.1 % 0.30 - 26.78 0.30
Q4 2015 54.60 8.4 % 0.61 - 54.60 0.61
Q1 2016 58.07 21.4 % 0.65 (2.02) 60.09 0.67
Q2 2016 54.14 51.0 % 0.60 (3.07) 57.21 0.64
Q3 2016 60.80 127.0 % 0.68 9.42 51.39 0.57
Q4 2016 51.71 (5.3 %) 0.57 (6.00) 57.71 0.64
Q1 2017 85.05 46.5 % 0.94 - 85.05 0.94
Q2 2017 69.99 29.3 % 0.78 - 69.99 0.78
Q3 2017 76.82 26.3 % 0.85 - 76.82 0.85
Q4 2017 63.12 22.1 % 0.70 (11.69) 74.81 0.83
Q1 2018 58.09 (31.7 %) 0.65 - 58.09 0.65
Q2 2018 18.73 (73.2 %) 0.21 - 18.73 0.21
Q3 2018 32.48 (57.7 %) 0.36 - 32.48 0.36
Q4 2018 32.47 (48.6 %) 0.36 - 32.47 0.36
Q1 2019 35.17 (39.5 %) 0.39 - 35.17 0.39
Q2 2019 15.35 (18.1 %) 0.17 - 15.35 0.17
Q3 2019 26.62 (18.1 %) 0.30 - 26.62 0.30
Q4 2019 69.79 115.0 % 0.78 13.39 56.41 0.63
Q1 2020 19.24 (45.3 %) 0.21 - 19.24 0.21
Q2 2020 6.99 (54.4 %) 0.08 - 6.99 0.08
Q3 2020 53.78 102.1 % 0.60 16.36 37.42 0.42
Q4 2020 51.98 (25.5 %) 0.58 34.87 17.11 0.19
Q1 2021 52.61 173.4 % 0.58 - 52.61 0.58
Q2 2021 47.54 579.9 % 0.53 - 47.54 0.53
Q3 2021 49.85 (7.3 %) 0.55 - 49.85 0.55
Q4 2021 108.60 108.9 % 1.21 10.35 98.25 1.09
Q1 2022 82.63 57.1 % 0.92 - 82.63 0.92
Q2 2022 69.52 46.2 % 0.77 - 69.52 0.77
Q3 2022 43.87 (12.0 %) 0.49 - 43.87 0.49
Q4 2022 78.44 (27.8 %) 0.87 - 78.44 0.87
Q1 2023 94.66 14.6 % 0.97 - 94.66 0.97
Q2 2023 53.01 (23.8 %) 0.54 - 53.01 0.54
Q3 2023 98.87 125.4 % 1.01 - 98.87 1.01
Q4 2023 113.65 44.9 % 1.16 - 113.65 1.16
Q1 2024 119.30 26.0 % 1.22 - 119.30 1.22
Q2 2024 111.84 111.0 % 1.14 - 111.84 1.14
Q3 2024 126.15 27.6 % 1.29 - 126.15 1.29
Q4 2024 113.90 0.2 % 1.17 - 113.90 1.17
2024 471.20 30.8 % 4.82 - 471.20 4.82


Financial results (Million)

Period Revenues Change Gross Income Change Operating Income Change
Q1 2015 240.40 15.8 % 102.13 16.6 % 39.67 (0.1 %)
Q2 2015 245.23 11.7 % 100.89 7.6 % 35.71 6.7 %
Q3 2015 223.93 16.2 % 87.92 16.7 % 26.37 21.7 %
Q4 2015 276.50 15.2 % 116.81 12.8 % 57.01 13.5 %
Q1 2016 285.03 18.6 % 132.53 29.8 % 61.90 56.1 %
Q2 2016 288.35 17.6 % 129.78 28.6 % 59.34 66.2 %
Q3 2016 273.17 22.0 % 122.38 39.2 % 51.80 96.4 %
Q4 2016 316.24 14.4 % 151.01 29.3 % 57.96 1.7 %
Q1 2017 302.75 6.2 % 143.60 8.4 % 85.82 38.6 %
Q2 2017 288.20 0.0 % 130.48 0.5 % 70.86 19.4 %
Q3 2017 295.25 8.1 % 136.77 11.8 % 76.36 47.4 %
Q4 2017 325.87 3.0 % 148.23 (1.8 %) 74.95 29.3 %
Q1 2018 308.59 1.9 % 131.73 (8.3 %) 59.44 (30.7 %)
Q2 2018 273.13 (5.2 %) 92.38 (29.2 %) 19.67 (72.2 %)
Q3 2018 280.94 (4.8 %) 101.37 (25.9 %) 33.44 (56.2 %)
Q4 2018 318.28 (2.3 %) 110.86 (25.2 %) 33.04 (55.9 %)
Q1 2019 321.15 4.1 % 120.26 (8.7 %) 41.24 (30.6 %)
Q2 2019 286.00 4.7 % 92.46 0.1 % 18.06 (8.2 %)
Q3 2019 301.34 7.3 % 107.78 6.3 % 30.99 (7.3 %)
Q4 2019 343.60 8.0 % 127.34 14.9 % 64.09 94.0 %
Q1 2020 314.61 (2.0 %) 105.76 (12.1 %) 26.42 (35.9 %)
Q2 2020 247.56 (13.4 %) 67.77 (26.7 %) 7.97 (55.9 %)
Q3 2020 350.79 16.4 % 132.62 23.0 % 50.51 63.0 %
Q4 2020 405.30 18.0 % 143.57 12.7 % 40.26 (37.2 %)
Q1 2021 494.67 57.2 % 176.82 67.2 % 72.91 176.0 %
Q2 2021 490.83 98.3 % 168.17 148.1 % 68.57 760.1 %
Q3 2021 544.12 55.1 % 192.46 45.1 % 69.95 38.5 %
Q4 2021 575.57 42.0 % 222.91 55.3 % 116.48 189.4 %
Q1 2022 609.40 23.2 % 231.69 31.0 % 109.93 50.8 %
Q2 2022 583.82 18.9 % 212.13 26.1 % 96.68 41.0 %
Q3 2022 600.89 10.4 % 211.47 9.9 % 84.19 20.4 %
Q4 2022 693.88 20.6 % 239.81 7.6 % 101.69 (12.7 %)
Q1 2023 716.64 17.6 % 266.79 15.1 % 132.49 20.5 %
Q2 2023 670.42 14.8 % 235.08 10.8 % 87.85 (9.1 %)
Q3 2023 749.83 24.8 % 280.86 32.8 % 130.97 55.6 %
Q4 2023 806.01 16.2 % 295.94 23.4 % 134.34 32.1 %
Q1 2024 784.06 9.4 % 293.36 10.0 % 143.22 8.1 %
Q2 2024 765.18 14.1 % 297.73 26.7 % 135.70 54.5 %
Q3 2024 847.73 13.1 % 322.99 15.0 % 161.42 23.3 %
Q4 2024 808.76 0.3 % 292.76 (1.1 %) 115.40 (14.1 %)
2024 3,205.73 8.9 % 1,206.84 11.9 % 567.12 12.0 %

Profitability

Period Gross Margin OIBDA Margin Net Margin Before Unusual Items
Q1 2015 41.98 % 21.38 % 15.76 %
Q2 2015 41.58 % 21.72 % 15.48 %
Q3 2015 41.54 % 21.77 % 15.49 %
Q4 2015 41.35 % 21.81 % 15.34 %
Q1 2016 42.51 % 23.29 % 17.20 %
Q2 2016 43.49 % 24.24 % 18.50 %
Q3 2016 44.66 % 25.57 % 19.88 %
Q4 2016 46.07 % 24.94 % 19.47 %
Q1 2017 46.32 % 26.38 % 21.29 %
Q2 2017 46.38 % 27.68 % 22.38 %
Q3 2017 46.73 % 29.19 % 24.08 %
Q4 2017 46.13 % 30.34 % 25.30 %
Q1 2018 44.93 % 28.26 % 22.97 %
Q2 2018 42.33 % 24.50 % 18.99 %
Q3 2018 39.86 % 21.41 % 15.49 %
Q4 2018 36.95 % 18.60 % 12.00 %
Q1 2019 35.60 % 17.66 % 9.96 %
Q2 2019 35.23 % 17.77 % 9.57 %
Q3 2019 35.16 % 17.58 % 8.93 %
Q4 2019 35.77 % 19.73 % 10.66 %
Q1 2020 34.79 % 18.58 % 9.44 %
Q2 2020 33.85 % 18.13 % 9.05 %
Q3 2020 34.50 % 19.13 % 9.55 %
Q4 2020 34.12 % 16.71 % 6.13 %
Q1 2021 34.76 % 18.09 % 7.62 %
Q2 2021 35.67 % 19.32 % 8.88 %
Q3 2021 35.20 % 18.83 % 8.64 %
Q4 2021 36.12 % 21.04 % 11.79 %
Q1 2022 36.72 % 21.66 % 12.54 %
Q2 2022 37.15 % 22.13 % 12.98 %
Q3 2022 37.06 % 22.17 % 12.42 %
Q4 2022 35.98 % 20.37 % 11.03 %
Q1 2023 35.84 % 20.47 % 11.04 %
Q2 2023 35.54 % 19.47 % 10.07 %
Q3 2023 36.12 % 20.16 % 11.48 %
Q4 2023 36.65 % 20.77 % 12.24 %
Q1 2024 36.72 % 20.83 % 12.78 %
Q2 2024 37.61 % 21.89 % 14.29 %
Q3 2024 37.78 % 22.23 % 14.70 %
Q4 2024 37.65 % - 14.70 %
2024 37.65 % - 14.70 %


Per Share Data (Riyal)

Compared With The
Period Shares Outstanding (M) EPS (Riyal) Earnings Per Share before unusual items (Riyal) Book Value (BV)
Q1 2015 90.00 1.72 1.56 14.74
Q2 2015 90.00 1.73 1.58 14.63
Q3 2015 90.00 1.79 1.63 14.86
Q4 2015 90.00 1.83 1.68 15.48
Q1 2016 90.00 1.95 1.97 16.15
Q2 2016 90.00 2.15 2.21 15.76
Q3 2016 90.00 2.53 2.48 16.26
Q4 2016 90.00 2.50 2.52 16.85
Q1 2017 90.00 2.80 2.79 17.78
Q2 2017 90.00 2.97 2.93 17.24
Q3 2017 90.00 3.15 3.22 18.05
Q4 2017 90.00 3.28 3.41 18.80
Q1 2018 90.00 2.98 3.11 19.41
Q2 2018 90.00 2.41 2.54 17.98
Q3 2018 90.00 1.92 2.05 18.34
Q4 2018 90.00 1.58 1.58 17.79
Q1 2019 90.00 1.32 1.32 18.07
Q2 2019 90.00 1.28 1.28 16.24
Q3 2019 90.00 1.22 1.22 16.54
Q4 2019 90.00 1.63 1.48 16.91
Q1 2020 90.00 1.46 1.31 16.57
Q2 2020 90.00 1.36 1.21 16.65
Q3 2020 90.00 1.66 1.33 17.25
Q4 2020 90.00 1.47 0.90 19.94
Q1 2021 90.00 1.84 1.27 19.89
Q2 2021 90.00 2.29 1.72 20.42
Q3 2021 90.00 2.24 1.86 20.86
Q4 2021 90.00 2.87 2.76 20.74
Q1 2022 90.00 3.21 3.09 21.70
Q2 2022 90.00 3.45 3.34 22.47
Q3 2022 90.00 3.38 3.27 21.96
Q4 2022 90.00 3.05 3.05 22.11
Q1 2023 97.68 2.93 2.93 32.03
Q2 2023 97.68 2.76 2.76 32.07
Q3 2023 97.68 3.33 3.33 32.64
Q4 2023 97.68 3.69 3.69 32.79
Q1 2024 97.68 3.94 3.94 34.02
Q2 2024 97.68 4.54 4.54 34.51
Q3 2024 97.68 4.82 4.82 34.96
Q4 2024 97.68 4.82 4.82 35.51

Multiple Ratios (End of Period Price)

Compared With The
Period P/E Adjusted P/E Price/book
Q1 2015 40.15 44.08 4.67
Q2 2015 45.84 50.27 5.43
Q3 2015 32.29 35.31 3.88
Q4 2015 27.26 29.73 3.23
Q1 2016 27.46 27.14 3.31
Q2 2016 28.54 27.81 3.89
Q3 2016 21.29 21.71 3.31
Q4 2016 27.05 26.85 4.01
Q1 2017 25.95 25.99 4.08
Q2 2017 26.81 27.16 4.62
Q3 2017 24.63 24.12 4.30
Q4 2017 21.93 21.10 3.82
Q1 2018 24.80 23.77 3.80
Q2 2018 28.42 26.97 3.81
Q3 2018 22.92 21.46 2.39
Q4 2018 25.39 25.39 2.25
Q1 2019 32.81 32.81 2.40
Q2 2019 34.90 34.90 2.76
Q3 2019 36.10 36.10 2.66
Q4 2019 25.93 28.53 2.50
Q1 2020 28.43 31.66 2.50
Q2 2020 31.13 34.94 2.55
Q3 2020 30.78 38.40 2.97
Q4 2020 35.71 58.36 2.63
Q1 2021 31.13 45.10 2.88
Q2 2021 37.67 50.14 4.22
Q3 2021 34.24 41.38 3.68
Q4 2021 28.37 29.55 3.93
Q1 2022 34.32 35.59 5.07
Q2 2022 34.85 36.05 5.35
Q3 2022 50.66 52.45 7.81
Q4 2022 52.67 52.67 7.27
Q1 2023 52.51 52.51 4.81
Q2 2023 60.71 60.71 5.23
Q3 2023 42.86 42.86 4.37
Q4 2023 46.59 46.59 5.24
Q1 2024 42.49 42.49 4.92
Q2 2024 34.08 34.08 4.49
Q3 2024 33.39 33.39 4.61
Q4 2024 31.10 31.10 4.22

Business Segments (Million)

Compared With The
Period Medical Services Medicine and Pharmaceutical Products
Q1 2015 224.02 16.38
Q2 2015 228.38 16.85
Q3 2015 215.41 8.52
Q4 2015 257.40 18.49
Q1 2016 276.15 8.88
Q2 2016 277.42 10.93
Q3 2016 265.04 8.13
Q4 2016 307.51 8.73
Q1 2017 239.94 62.81
Q2 2017 229.31 58.90
Q3 2017 235.08 60.17
Q4 2017 241.44 84.43
Q1 2018 236.76 71.84
Q2 2018 205.73 67.39
Q3 2018 218.43 62.50
Q4 2018 228.74 89.55
Q1 2019 239.22 81.93
Q2 2019 210.95 75.06
Q3 2019 232.55 68.79
Q4 2019 259.40 84.20
Q1 2020 227.83 86.77
Q2 2020 166.96 80.60
Q3 2020 260.50 90.30
Q4 2020 309.74 95.55
Q1 2021 378.70 115.97
Q2 2021 374.54 116.29
Q3 2021 412.23 131.88
Q4 2021 472.23 103.34
Q1 2022 470.53 138.87
Q2 2022 475.30 108.52
Q3 2022 438.86 162.03
Q4 2022 547.10 146.77
Q1 2023 530.59 186.05
Q2 2023 513.01 157.40
Q3 2023 518.40 231.43
Q4 2023 597.28 208.74
Q1 2024 574.66 209.40
Q2 2024 550.68 214.50
Q3 2024 628.19 219.55

Analysts Estimates (Million)

Item Q4 2024 (e) Q4 2024 (a) Change‬
Average 133.44 113.90 (14.6 %)

Estimates vs Actual (Million)

Item Q4 2024 (e) Q4 2024 (a) Change
OSOOL AND BAKHEET 124.35 113.90 (8.4) %
AlJazira Capital 131.40 113.90 (13.3) %
Al Rajhi Capital 137.00 113.90 (16.9) %
SNB Capital 141.00 113.90 (19.2) %


Financial Ratios
Current
Market Cap (M Riyal) 12,835.15
Enterprise Value (EV) (M) 14,838.99
Shares Outstanding ((M)) 97.68
EPS ( Riyal) (TTM) 4.82
Book Value (BV) ( Riyal) 35.51
Par Value ( Riyal) 10.00
Adjusted P/E (Last12) 27.24
P/E (TTM) 27.24
Price/book 3.70
Return on Average Assets (%) (TTM) 7.3
Return on Average Equity (%) (TTM) 9.7
more

Share Price

Dallah Healthcare Co.
131.40
8.40 6.83 %

Dallah Healthcare Co. (DALLAH HEALTH)

More

Comments {{getCommentCount()}}

Be the first to comment

{{Comments.indexOf(comment)+1}}
{{comment.FollowersCount}}
{{comment.CommenterComments}}

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

{{comment.DisplayName}} حساب موثّق

{{comment.ElapsedTime}}
loader Train
loader Train
Sorry: the validity period has ended to comment on this news
Opinions expressed in the comments section do not reflect the views of Argaam. Abusive comments of any kind will be removed. Political or religious commentary will not be tolerated.